1 EXECUTIVE SUMMARY
1.1 OVERVIEW 14
1.2 MARKET SYNOPSIS 14
2 MARKET INTRODUCTION
2.1 SCOPE OF THE STUDY 15
2.2 RESEARCH OBJECTIVE 15
3 RESEARCH METHODOLOGY
3.1 OVERVIEW 16
3.2 DATA MINING 16
3.3 SECONDARY RESEARCH 16
3.4 PRIMARY RESEARCH 18
3.4.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS 18
3.4.2 BREAKDOWN OF PRIMARY RESPONDENTS 19
3.5 FORECASTING METHODS 20
3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 21
3.6.1 BOTTOM-UP APPROACH 21
3.6.2 TOP-DOWN APPROACH 22
3.7 DATA TRIANGULATION 22
3.8 VALIDATION 22
3.9 ASSUMPTIONS AND LIMITATIONS 23
3.9.1 ASSUMPTIONS AND LIMITATIONS 23
3.9.2 MARKET FACTORS 23
4 MARKET DYNAMICS
4.1 OVERVIEW 25
4.2 DRIVERS 26
4.2.1 INCREASING NUMBER OF COVID-19 CASES 26
4.2.2 GOVERNMENT AND PRIVATE FUNDS AS WELL AS SUPPORT FOR RESEARCH & DEVELOPMENT 26
4.2.3 RISING NUMBER OF EMERGENCY USE AUTHORIZATIONS (EUA) FOR DIAGNOSTIC KITS AND DEVICES 26
4.2.4 DEVELOPMENTS AND SUPPORT BY NON-MEDICAL DEVICE/DIAGNOSTIC COMPANIES 27
4.3 RESTRAINTS 28
4.3.1 RESTRICTIONS ON EXPORT OF DIAGNOSTIC KITS 28
4.3.2 ACCURACY OF TEST RESULTS 28
4.4 OPPORTUNITIES 28
4.4.1 DEVELOPMENT OF QUICK, ACCURATE, AND AFFORDABLE TESTS 28
4.4.2 COLLABORATION OF MAJOR PLAYERS WITH SMALL PLAYERS 28
5 MARKET FACTOR ANALYSIS
5.1 PORTER’S FIVE FORCES MODEL 29
5.1.1 THREAT OF NEW ENTRANTS 29
5.1.2 BARGAINING POWER OF SUPPLIERS 30
5.1.3 THREAT OF SUBSTITUTES 30
5.1.4 BARGAINING POWER OF BUYERS 30
5.1.5 INTENSITY OF RIVALRY 30
5.2 SUPPLY CHAIN ANALYSIS 31
5.2.1 R&D AND DESIGNING 32
5.2.2 MANUFACTURING 32
5.2.3 DISTRIBUTION 32
5.2.4 MARKETING & SALES 32
5.2.5 POST-SALES MONITORING 32
5.3 IMPACT OF COVID-19 ON SUPPLY OF DIAGNOSTIC DEVICES 32
6 COVID-19 DIAGNOSTICS MARKET, BY TYPE
6.1 OVERVIEW 33
6.2 MOLECULAR TESTS 34
6.3 SEROLOGY TESTS 36
7 COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
7.1 OVERVIEW 38
7.2 RT-PCR 40
7.3 ISOTHERMAL AMPLIFICATION 40
7.4 CRISPR 41
7.5 ELISA 42
7.6 HYBRIDIZATION 43
7.7 OTHERS 43
8 COVID-19 DIAGNOSTICS MARKET, BY END USER
8.1 OVERVIEW 44
8.2 HOSPITALS 45
8.3 PUBLIC HEALTH LABS 46
8.4 PRIVATE OR COMMERCIAL LABS 47
9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION
9.1 OVERVIEW 48
9.2 EUROPE 50
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1 WESTERN EUROPE 52
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.1 GERMANY 53
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.2 SPAIN 54
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.3 ITALY 55
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.4 UK 56
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.5 FRANCE 57
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.1.6 REST OF WESTERN EUROPE 58
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.2.2 EASTERN EUROPE 59
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3 AMERICAS 61
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1 NORTH AMERICA 63
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1.1 US 64
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.1.2 CANADA 65
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.3.2 LATIN AMERICA 66
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4 ASIA-PACIFIC 68
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.1 INDIA 70
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.2 AUSTRALIA 71
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.3 SOUTH KOREA 72
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.4 JAPAN 73
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.5 CHINA 74
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.4.6 REST OF ASIA-PACIFIC 75
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5 MIDDLE EAST & AFRICA 77
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5.1 MIDDLE EAST 79
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
9.5.2 AFRICA 80
COVID-19 DIAGNOSTICS MARKET, BY TYPE
COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY
COVID-19 DIAGNOSTICS MARKET, BY END USER
10 COMPETITIVE LANDSCAPE
10.1 OVERVIEW 81
10.2 MAJOR PLAYERS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 81
10.3 GLOBAL COVID-19 DIAGNOSTICS MARKET INSIGHTS 82
10.4 COMPETITIVE BENCHMARKING 83
10.5 COMPETITOR DASHBOARD 84
10.6 MAJOR GROWTH STRATEGIES IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 85
10.7 LEADING PLAYERS IN TERMS OF NUMBER OF DEVELOPMENTS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 86
10.8 KEY DEVELOPMENTS & GROWTH STRATEGIES 86
10.8.1 PRODUCT LAUNCHES 87
10.8.2 ACQUISITIONS 88
10.8.3 CONTRACTS 88
11 COMPANY PROFILES
11.1 BECTON, DICKINSON AND COMPANY 89
11.1.1 COMPANY OVERVIEW 89
11.1.2 FINANCIAL OVERVIEW 90
11.1.3 PRODUCTS/SERVICES OFFERED 90
11.1.4 KEY DEVELOPMENTS 91
11.1.5 SWOT ANALYSIS 91
11.1.6 KEY STRATEGIES 91
11.2 BIO-RAD LABORATORIES, INC. 92
11.2.1 COMPANY OVERVIEW 92
11.2.2 FINANCIAL OVERVIEW 92
11.2.3 PRODUCTS/SERVICES OFFERED 93
11.2.4 KEY DEVELOPMENTS 93
11.2.5 SWOT ANALYSIS 94
11.2.6 KEY STRATEGIES 94
11.3 DANAHER CORPORATION 95
11.3.1 COMPANY OVERVIEW 95
11.3.2 FINANCIAL OVERVIEW 96
11.3.3 PRODUCTS/SERVICES OFFERED 96
11.3.4 KEY DEVELOPMENTS 97
11.3.5 SWOT ANALYSIS 97
11.3.6 KEY STRATEGIES 97
11.4 ABBOTT 98
11.4.1 COMPANY OVERVIEW 98
11.4.2 FINANCIAL OVERVIEW 99
11.4.3 PRODUCTS/SERVICES OFFERED 99
11.4.4 KEY DEVELOPMENTS 100
11.4.5 SWOT ANALYSIS 100
11.4.6 KEY STRATEGIES 100
11.5 F. HOFFMANN-LA ROCHE LTD 101
11.5.1 COMPANY OVERVIEW 101
11.5.2 FINANCIAL OVERVIEW 102
11.5.3 PRODUCTS/SERVICES OFFERED 102
11.5.4 KEY DEVELOPMENTS 103
11.5.5 SWOT ANALYSIS 103
11.5.6 KEY STRATEGIES 103
11.6 BIOMÉRIEUX SA 104
11.6.1 COMPANY OVERVIEW 104
11.6.2 FINANCIAL OVERVIEW 104
11.6.3 PRODUCTS/SERVICES OFFERED 105
11.6.4 PRODUCTS/SERVICES PIPELINE 105
11.6.5 KEY DEVELOPMENTS 105
11.6.6 SWOT ANALYSIS 106
11.6.7 KEY STRATEGIES 106
11.7 GENMARK DIAGNOSTICS, INC. 107
11.7.1 COMPANY OVERVIEW 107
11.7.2 FINANCIAL OVERVIEW 107
11.7.3 PRODUCTS/SERVICES OFFERED 108
11.7.4 KEY DEVELOPMENTS 108
11.7.5 SWOT ANALYSIS 108
11.7.6 KEY STRATEGIES 108
11.8 THERMO FISHER SCIENTIFIC INC. 109
11.8.1 COMPANY OVERVIEW 109
11.8.2 FINANCIAL OVERVIEW 109
11.8.3 PRODUCTS/SERVICES OFFERED 110
11.8.4 KEY DEVELOPMENTS 110
11.8.5 SWOT ANALYSIS 110
11.8.6 KEY STRATEGIES 111
11.9 QIAGEN 112
11.9.1 COMPANY OVERVIEW 112
11.9.2 FINANCIAL OVERVIEW 113
11.9.3 PRODUCTS/SERVICES OFFERED 113
11.9.4 KEY DEVELOPMENTS 114
11.9.5 SWOT ANALYSIS 114
11.9.6 KEY STRATEGIES 114
11.10 SIEMENS AG 115
11.10.1 COMPANY OVERVIEW 115
11.10.2 FINANCIAL OVERVIEW 115
11.10.3 PRODUCTS/SERVICES OFFERED 116
11.10.4 KEY DEVELOPMENTS 116
11.10.5 SWOT ANALYSIS 116
11.10.6 KEY STRATEGIES 117
12 APPENDIX
12.1 REFERENCES 118
12.2 RELATED REPORTS 119
13 LIST OF TABLES
TABLE 1 LIST OF ASSUMPTIONS AND LIMITATIONS 23
TABLE 2 NUMBER OF NEW CASES IN COUNTRIES THAT ARE MOST AFFECTED BY COVID-19 AS OF 18 MAY 2022 26
TABLE 3 DEVELOPMENTS BY PHARMACEUTICAL COMPANIES TO BOOST THE TESTING OF COVID-19 27
TABLE 4 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 34
TABLE 5 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 MOLECULAR TESTS DURING THE PUBLIC HEALTH EMERGENCY 35
TABLE 6 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR MOLECULAR TESTS, BY REGION, 2022-2030 (USD MILLION) 35
TABLE 7 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 SEROLOGICAL TESTS DURING THE PUBLIC HEALTH EMERGENCY 36
TABLE 8 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR SEROLOGY TESTS, BY REGION, 2022-2030 (USD MILLION) 37
TABLE 9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 39
TABLE 10 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR RT-PCR, BY REGION, 2022-2030 (USD MILLION) 40
TABLE 11 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 DURING THE PUBLIC HEALTH EMERGENCY: USING ISOTHERMAL AMPLIFICATION TECHNOLOGY 41
TABLE 12 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR ISOTHERMAL AMPLIFICATION, BY REGION, 2022-2030 (USD MILLION) 41
TABLE 13 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR CRISPR, BY REGION, 2022-2030 (USD MILLION) 42
TABLE 14 US FOOD AND DRUG ADMINISTRATION (FDA) REVISED POLICY FOR CORONAVIRUS DISEASE-2019 DURING THE PUBLIC HEALTH EMERGENCY: USING ELISA 42
TABLE 15 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR ELISA, BY REGION, 2022-2030 (USD MILLION) 43
TABLE 16 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR HYBRIDIZATION, BY REGION, 2022-2030 (USD MILLION) 43
TABLE 17 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 45
TABLE 18 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR HOSPITALS, BY REGION, 2022-2030 (USD MILLION) 46
TABLE 19 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR PUBLIC HEALTH LABS, BY REGION, 2022-2030 (USD MILLION) 46
TABLE 20 GLOBAL COVID-19 DIAGNOSTICS MARKET, FOR PRIVATE OR COMMERCIAL LABS, BY REGION, 2022-2030 (USD MILLION) 47
TABLE 21 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 49
TABLE 22 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 50
TABLE 23 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 51
TABLE 24 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 51
TABLE 25 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 51
TABLE 26 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 52
TABLE 27 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 52
TABLE 28 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 53
TABLE 29 GERMANY: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 53
TABLE 30 GERMANY: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 53
TABLE 31 GERMANY: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 54
TABLE 32 SPAIN: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 54
TABLE 33 SPAIN: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 54
TABLE 34 SPAIN: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 55
TABLE 35 ITALY: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 55
TABLE 36 ITALY: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 55
TABLE 37 ITALY: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 56
TABLE 38 UK: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 56
TABLE 39 UK: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 56
TABLE 40 UK: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 57
TABLE 41 FRANCE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 57
TABLE 42 FRANCE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 57
TABLE 43 FRANCE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 58
TABLE 44 REST OF WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 58
TABLE 45 REST OF WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 58
TABLE 46 REST OF WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 59
TABLE 47 EASTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 59
TABLE 48 EASTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 59
TABLE 49 EASTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 60
TABLE 50 AMERICAS: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 61
TABLE 51 AMERICAS: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 62
TABLE 52 AMERICAS: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 62
TABLE 53 AMERICAS: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 62
TABLE 54 NORTH AMERICA: COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 63
TABLE 55 NORTH AMERICA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 63
TABLE 56 NORTH AMERICA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 64
TABLE 57 NORTH AMERICA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 64
TABLE 58 US: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 64
TABLE 59 US: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 65
TABLE 60 US: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 65
TABLE 61 CANADA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 65
TABLE 62 CANADA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 66
TABLE 63 CANADA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 66
TABLE 64 LATIN AMERICA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 66
TABLE 65 LATIN AMERICA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 67
TABLE 66 LATIN AMERICA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 67
TABLE 67 ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022-2030 (USD MILLION) 69
TABLE 68 ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 69
TABLE 69 ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 69
TABLE 70 ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 70
TABLE 71 INDIA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 70
TABLE 72 INDIA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 70
TABLE 73 INDIA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 71
TABLE 74 AUSTRALIA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 71
TABLE 75 AUSTRALIA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 71
TABLE 76 AUSTRALIA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 72
TABLE 77 SOUTH KOREA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 72
TABLE 78 SOUTH KOREA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 72
TABLE 79 SOUTH KOREA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 73
TABLE 80 JAPAN: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 73
TABLE 81 JAPAN: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 73
TABLE 82 JAPAN: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 74
TABLE 83 CHINA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 74
TABLE 84 CHINA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 74
TABLE 85 CHINA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 75
TABLE 86 REST OF ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 75
TABLE 87 REST OF ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 75
TABLE 88 REST OF ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 76
TABLE 89 MIDDLE EAST & AFRICA: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022-2030 (USD MILLION) 77
TABLE 90 MIDDLE EAST & AFRICA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 78
TABLE 91 MIDDLE EAST & AFRICA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 78
TABLE 92 MIDDLE EAST & AFRICA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 78
TABLE 93 MIDDLE EAST: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 79
TABLE 94 MIDDLE EAST: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 79
TABLE 95 MIDDLE EAST: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 79
TABLE 96 AFRICA: COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022-2030 (USD MILLION) 80
TABLE 97 AFRICA: COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022-2030 (USD MILLION) 80
TABLE 98 AFRICA: COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022-2030 (USD MILLION) 80
TABLE 99 MAJOR PLAYERS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 81
TABLE 100 COMPETITOR DASHBOARD: GLOBAL COVID-19 DIAGNOSTICS MARKET 84
TABLE 101 THE MOST ACTIVE PLAYER IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 86
TABLE 102 PRODUCT LAUNCHES 87
TABLE 103 ACQUISITIONS 88
TABLE 104 CONTRACTS 88
TABLE 105 BECTON, DICKINSON AND COMPANY: PRODUCTS/SERVICES OFFERED 90
TABLE 106 BECTON, DICKINSON AND COMPANY: KEY DEVELOPMENTS 91
TABLE 107 BIO-RAD LABORATORIES, INC.: PRODUCTS/SERVICES OFFERED 93
TABLE 108 BIO-RAD LABORATORIES, INC.: KEY DEVELOPMENTS 93
TABLE 109 DANAHER CORPORATION: PRODUCTS/SERVICES OFFERED 96
TABLE 110 DANAHER CORPORATION: KEY DEVELOPMENTS 97
TABLE 111 ABBOTT: PRODUCTS/SERVICES OFFERED 99
TABLE 112 ABBOTT: KEY DEVELOPMENTS 100
TABLE 113 F. HOFFMANN-LA ROCHE LTD: PRODUCTS/SERVICES OFFERED 102
TABLE 114 F. HOFFMANN-LA ROCHE LTD: KEY DEVELOPMENTS 103
TABLE 115 BIOMÉRIEUX SA: PRODUCTS/SERVICES OFFERED 105
TABLE 116 BIOMÉRIEUX SA: PRODUCTS/SERVICES OFFERED 105
TABLE 117 BIOMÉRIEUX SA: KEY DEVELOPMENTS 105
TABLE 118 GENMARK DIAGNOSTICS, INC.: PRODUCTS/SERVICES OFFERED 108
TABLE 119 GENMARK DIAGNOSTICS, INC.: KEY DEVELOPMENTS 108
TABLE 120 THERMO FISHER SCIENTIFIC INC.: PRODUCTS/SERVICES OFFERED 110
TABLE 121 THERMO FISHER SCIENTIFIC INC.: KEY DEVELOPMENTS 110
TABLE 122 QIAGEN: PRODUCTS/SERVICES OFFERED 113
TABLE 123 QIAGEN: KEY DEVELOPMENTS 114
TABLE 124 SIEMENS AG: PRODUCTS/SERVICES OFFERED 116
TABLE 125 SIEMENS AG: KEY DEVELOPMENTS 116
14 LIST OF FIGURES
FIGURE 1 GLOBAL COVID-19 DIAGNOSTICS MARKET STRUCTURE 15
FIGURE 2 BOTTOM-UP AND TOP-DOWN APPROACHES 21
FIGURE 3 MARKET DYNAMICS: GLOBAL COVID-19 DIAGNOSTICS MARKET 25
FIGURE 4 PORTER’S FIVE FORCES ANALYSIS: GLOBAL COVID-19 DIAGNOSTICS MARKET 29
FIGURE 5 SUPPLY CHAIN ANALYSIS: GLOBAL COVID-19 DIAGNOSTICS MARKET 31
FIGURE 6 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2022 (%) 33
FIGURE 7 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TYPE, 2021 & 2030 (USD MILLION) 34
FIGURE 8 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2022 (%) 38
FIGURE 9 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY TECHNOLOGY, 2021 & 2030 (USD MILLION) 39
FIGURE 10 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2022 (%) 44
FIGURE 11 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY END USER, 2021 & 2030 (USD MILLION) 45
FIGURE 12 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022 (%) 48
FIGURE 13 GLOBAL COVID-19 DIAGNOSTICS MARKET, BY REGION, 2021 & 2030 (USD MILLION) 48
FIGURE 14 EUROPE: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022 (%) 50
FIGURE 15 WESTERN EUROPE: COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (%) 52
FIGURE 16 AMERICAS: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022 (%) 61
FIGURE 17 NORTH AMERICA: COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (%) 63
FIGURE 18 ASIA-PACIFIC: COVID-19 DIAGNOSTICS MARKET, BY COUNTRY, 2022 (%) 68
FIGURE 19 MIDDLE EAST & AFRICA: COVID-19 DIAGNOSTICS MARKET, BY REGION, 2022 (%) 77
FIGURE 20 BENCHMARKING OF MAJOR COMPETITORS 83
FIGURE 21 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN THE GLOBAL COVID-19 DIAGNOSTICS MARKET 85
FIGURE 22 GLOBAL COVID-19 DIAGNOSTICS MARKET, KEY DEVELOPMENTS & GROWTH STRATEGIES (%) 86
FIGURE 23 BECTON, DICKINSON AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT 90
FIGURE 24 BECTON, DICKINSON AND COMPANY: SWOT ANALYSIS 91
FIGURE 25 BIO-RAD LABORATORIES, INC.: FINANCIAL OVERVIEW SNAPSHOT 92
FIGURE 26 BIO-RAD LABORATORIES, INC.: SWOT ANALYSIS 94
FIGURE 27 DANAHER CORPORATION: FINANCIAL OVERVIEW SNAPSHOT 96
FIGURE 28 DANAHER CORPORATION: SWOT ANALYSIS 97
FIGURE 29 ABBOTT: FINANCIAL OVERVIEW SNAPSHOT 99
FIGURE 30 ABBOTT: SWOT ANALYSIS 100
FIGURE 31 F. HOFFMANN-LA ROCHE LTD: FINANCIAL OVERVIEW SNAPSHOT 102
FIGURE 32 F. HOFFMANN-LA ROCHE LTD: SWOT ANALYSIS 103
FIGURE 33 BIOMÉRIEUX SA: FINANCIAL OVERVIEW SNAPSHOT 104
FIGURE 34 BIOMÉRIEUX SA: SWOT ANALYSIS 106
FIGURE 35 GENMARK DIAGNOSTICS, INC.: FINANCIAL OVERVIEW SNAPSHOT 107
FIGURE 36 GENMARK DIAGNOSTICS, INC.: SWOT ANALYSIS 108
FIGURE 37 THERMO FISHER SCIENTIFIC INC.: FINANCIAL OVERVIEW SNAPSHOT 109
FIGURE 38 THERMO FISHER SCIENTIFIC INC.: SWOT ANALYSIS 110
FIGURE 39 QIAGEN: FINANCIAL OVERVIEW 113
FIGURE 40 QIAGEN: SWOT ANALYSIS 114
FIGURE 41 SIEMENS AG: FINANCIAL OVERVIEW SNAPSHOT 115
FIGURE 42 SIEMENS AG: SWOT ANALYSIS 116